Precision of the Icare200 for Measuring Intraocular Pressure

Sponsor
University Hospital, Clermont-Ferrand (Other)
Overall Status
Completed
CT.gov ID
NCT05147610
Collaborator
(none)
171
1
1
7.6
22.4

Study Details

Study Description

Brief Summary

In adult patients, intraocular pression readings are often taken with an air puff tonometer or goldmann tonometer. The current gold standard for IOP measurement is the Goldmann Applanation Tonometry (GAT). In some patients, measurement of intraocular pressure taken by applanation or by air puff may prove to be impossible for various reasons (obesity, handicap, mental disorder, blindness for Air Puff Tonometry, Anxiety, etc).

There are also many other devices that can be used to measure IOP, including those using rebound tonometry like the Icare 200.

The rebound tonometer would systematize IOP screening because of its ease of use, provided its measurements are reliable. In this prospective study, investigators will be measuring participant's IOP with Goldmann Applanation Tonometry, Icare 200 Tonometer and Air Puff Tonometry to see if there is an agreement in IOP between the different devices. Investigators will also look if there is a concordance between central corneal thickness and IOP. Moreover, investigators will look if there is a IOP concordance between the 3 different devices for hight BMI people. Indeed, higher body mass index tend to have difficulties with proper positioning at the slit lamp that may lead to inaccurate GAT measurements. Additionally, stress level of the patients with different tonometry devices will be recorded using a visual analog scale.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Intraocular pression
N/A

Detailed Description

Goldmann applanation tonometry remains the gold standard for intraocular pressure measurement in 2021. It provides the most exact approximation of true intraocular pressure based on Imbert Fick's law. The statistical normal (Gaussian distribution) of IOP is 15.8 plus or minus 5.14mmHg (2 standard deviations). Thus, an IOP value is considered to be pathological if it is greater than 21mmHg. In practice, the measurement with the Goldmann tonometer is done in a seated position due to the need to be installed behind a slit lamp. An anesthetic drop such as oxybuprocaine or tetracaine is instilled onto the ocular surface followed by a fluorescein drop. GAT may be associated with discomfort due to the need for topical anaesthesia which causes a burning sensation during about 30 secondes. Moreover, the patient must be compliant and the need to be seated makes measurement very difficult for some patients: pediatric, dementia, hight BMI or elderly people.

Rebound tonometers determine intraocular pressure by bouncing a small plastic tipped metal probe against the cornea.

As IOP increases, impact time decreases and rebound increases. It is portable, does not require the use of eye drops and is particularly suitable for children and non-cooperative patients. The examination is painless and can be performed without contact anesthesia. Different versions of tonometer using this principle exist. With the Icare 200 six measurements are taken. The 2 extreme values are eliminated and the average of the 4 remaining values gives the IOP.

In healthy subjects, the Icare tonometer gives results comparable to those of the Goldmann tonometer (1) with differences of less than 3 mmHg in 80% of cases (2).

In the literature, the type of rebound tonometer differs from that used in our study. Most of the previous studies compare the Icare RT01i, the Icare PRO, the Icare ONE, the Icare HOME or even the Icare 100 which are much older versions.

The Icare 200, the most recent model dating from 2018, has benefited from technical improvements. Intraocular pressure can be taken in any position.

Only one article in the literature has studied the diagnostic performance of Icare200 to date. In this study, Icare200 was compared with the Perkins tonometer in 2 groups of people, one group of healthy subjects and one group of patients with congenital glaucoma.

To date, we have no studies investigating the diagnostic performance of the iCare200 compared to the Goldmann tonometer. It is the interest of this study to compare the relationship of the IOP measurements obtained by Icare 200, Air Puff Tonometer and Goldmann Applanation Tonometry.

For this we have chosen to carry out a prospective study. We have chosen to include consenting adult patients consulting in ophthalmology consultation at Clermont-Ferrand University Hospital. This results in a large panel of patients with different IOP in order to observe enough IOP variability.

IOP measurements appear to correlate with corneal pachymetry (3). So, we chose to organize 4 subgroups according to pachymetry estimated by TONOREF III (high pachymetry, i.e. corneal thickness greater than 560um; low pachymetry, i.e. corneal thickness less than 500um; normal pachymetry, i.e. corneal thickness between 500 and 560um and subnormal pachymetry, i.e. corneal thickness between 500 and 520um).

Patient anxiety during tonometry will be measured using a visual analogue scale.

Study Design

Study Type:
Interventional
Actual Enrollment :
171 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
all participants receive the same interventionall participants receive the same intervention
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Estimation of the Precision of the Icare200 in the Measurement of Intraocular Pressure in Comparison to the Gold Standard : Goldmann Applanation Tonometer
Actual Study Start Date :
Dec 1, 2021
Actual Primary Completion Date :
Apr 22, 2022
Actual Study Completion Date :
Jul 21, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: patients requiring an IOP (intra-Ocular Pression) measurement

group representing adults patients in ophthalmologic consultation requiring an IOP measurement

Diagnostic Test: Intraocular pression
First, measurement of the eye pressure by air-puff tonometry and estimation of the pachymetries with the TONOREF III. Secondly, measurement of the eye pressure by GAT. Thirdly, measurement of the eye pressure by Icare 200.

Outcome Measures

Primary Outcome Measures

  1. mean difference (mmHg) between the Icare200 rebound tonometer and the Goldmann applanation tonometer [Day 0]

    To evaluate the concordance of Goldmann tonometer and Icare 200 tonometer

Secondary Outcome Measures

  1. Diagnostic Performance [Day 0]

    To evaluate the ability of detect ocular hypertension (>21mmHg)

  2. Correlation between central corneal thickness and IOP [Day 0]

    To evaluate the central corneal thickness on IOP measurement by Goldmann tonometer, Icare 200 tonometer and air puff tonometer

  3. Effect of BMI on IOP [Day 0]

    To compare IOP measurement between Goldmann tonometer, Air puff tonometer and Icare 200 tonometer depending of BMI (<29,9 ; 30-34,9 ; 35-39,9 ; >40)

  4. Patient comfort during tonometry [Day 0]

    To evaluate the discomfort felt by the patient after measurement by Icare 200 with a verbal scale

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult man ou woman who consults in ophthalmology for a reason justifying an IOP measurement

  • Able to give informed consent

  • Being affiliated with a social security system

Exclusion Criteria:
  • Participants who are unable to have IOP measured by Goldmann Tonometry

  • Participants who are unable to have IOP measured by air puff Tonometry

  • Age younger than 18 years

  • Inability to sit

  • Corneal ulcer

  • Refractive surgery

  • Corneal Astigmatism >3D

  • Participants who wear contact lenses

  • Pregnancy

  • Unable to give consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU de Clermont-Ferrand Clermont-Ferrand France 63000

Sponsors and Collaborators

  • University Hospital, Clermont-Ferrand

Investigators

  • Principal Investigator: Adrien Coutu, University Hospital, Clermont-Ferrand

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier:
NCT05147610
Other Study ID Numbers:
  • RBHP 2021 COUTU
  • 2021-A00556-35
First Posted:
Dec 7, 2021
Last Update Posted:
Jul 25, 2022
Last Verified:
Jul 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Clermont-Ferrand
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 25, 2022